What is Prostatic Artery Embolization (PAE)?
PAE is a minimally invasive radiological procedure performed under local anesthesia that reduces prostatic blood flow through selective embolization of prostatic vessels using permanent embolic agents (typically microparticles 100-500 µm), aimed at treating moderate-to-severe lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH). 1
Mechanism of Action
PAE works through a dual mechanism:
- Induces ischemic necrosis of hyperplastic prostatic tissue, leading to prostate volume reduction
- Decreases neuromuscular tone, addressing both static (anatomical) and dynamic (functional) components of bladder outlet obstruction 2
The procedure targets the prostatic arteries bilaterally through catheter-based delivery of embolic material, causing controlled tissue infarction specifically within the transitional zone where BPH develops 1, 3.
Technical Approach
Access route: Can be performed via femoral or radial artery approach, with radial access generally preferred by patients though anatomy should guide selection 4
Embolic agents: Non-resorbable particles (100-500 µm) are standard; liquid embolics (e.g., Glubran) are used in select centers but require additional validation 5
Imaging guidance: Advanced techniques including cone-beam CT help identify prostatic arteries and avoid non-target embolization, though this increases radiation exposure 1, 4
Clinical Positioning and Outcomes
According to the 2026 European Association of Urology Guidelines, PAE should be offered to men with moderate-to-severe LUTS/BPH who wish to consider minimally invasive options and accept less-optimal outcomes compared with TURP (weak recommendation). 1
Critical caveat: PAE must only be performed in units where urologists work collaboratively with trained interventional radiologists for patient selection and follow-up (strong recommendation). 1
Comparative Effectiveness
Versus TURP (gold standard):
- Symptom improvements occur but are inferior to TURP in functional outcomes 1, 6
- Higher retreatment rates than TURP 1, 6
- Lower blood loss, shorter catheterization and hospitalization times 6
- Better preservation of antegrade ejaculation 6
Versus medical management: PAE demonstrates clear superiority over combined medical therapy in quality of life, IPSS scores, and erectile function 7
Patient Selection Criteria
Ideal candidates:
- Men seeking minimally invasive alternatives to surgery
- Patients with large prostate volumes
- Those with significant comorbidities or on anticoagulation 5
- Men prioritizing preservation of ejaculatory function
- Patients willing to accept higher retreatment probability
Important exclusion consideration: Patients with catheter-dependent urinary retention should preferentially receive resective technologies, not PAE 7
Safety Profile and Limitations
Unique consideration: PAE is the only BPH treatment requiring radiation exposure to the patient 7
Common adverse events:
- Post-embolization syndrome (pain, dysuria)
- Hematuria
- Urinary tract infection
- Transient urinary symptoms 1
Retreatment rates: Significantly higher than ablative surgical techniques, which must be discussed during patient counseling 1, 5
Current Guideline Status
PAE remains under investigation according to both EAU and AUA guidelines 1. The 2026 AUA Guidelines now include PAE as a viable option for managing BPH-related LUTS, representing growing acceptance 3.
The procedure has matured from experimental to an evidence-based treatment option, though it occupies a specific niche rather than replacing standard surgical approaches. Success depends heavily on operator expertise, appropriate patient selection through multidisciplinary evaluation, and realistic patient expectations regarding outcomes and potential need for retreatment 3, 5, 4.